There was also a weak trend towards abnormal LPS levels in non-obese RA patients (p = 0.095), and abnormal fecal calprotectin levels in patients treated with TNF inhibitors (p = 0.084) (Table 3). This evidence concerns the gene TNF and rheumatoid arthritis.